The Senate passed its version of the GOP megabill on Tuesday, and big players across the health care industry have been quick ...

The HHS wants to move oversight of the controversial drug discount program to the CMS, which has a more aggressive history ...

In a webinar, panelists discuss Trump's 2025 drug pricing policies, focusing on the Most Favored Nation order, pharmacy benefit manager reform, and implications for manufacturers and patients.

In his first term, Trump made a lot of noise about lowering drug prices but accomplished little of consequence. The noise continues, but it is now accompanied by new ill-conceived initiatives, ...

A new state law regulating third-party health care companies can go into effect Tuesday as planned for much of Iowa, but not ...

The Senate version of the legislation makes even steeper cuts to Medicaid than the $800 billion slashed in the House-passed version of the bill.

Oklahoma lawmakers passed HB 2048 to protect the 340B Drug Pricing Program, overriding a veto amid growing pressure from pharmaceutical interests.

The bill would cut $1.1 trillion in health-care spending and result in 11.8 million people losing health coverage over the ...

The pharmaceutical industry’s lobbying muscle scored a high-stakes victory on Monday when the Senate parliamentarian reversed a previous decision and ruled that the Optimizing Research Progress Hope ...

The Senate Parliamentarian reversed course on a small provision in the One Big Beautiful Bill Act that could boost cures for ...

Ted Okon, MBA, of the Community Oncology Alliance discusses how community oncology faces a revenue crisis due to the ...

T he Senate has spent all day slowly trudging through an hours-long vote-a-thon, a series of votes on amendments to this year ...